High expression of MYL5 and MYO1B mRNAs indicates an opposite outcome compared to MYO18B expression in survival of HCC patients which may possibly be mediated by bFGF-induced counteraction of IFN-γ signaling and therefore, detailed studies on the signaling pathways regulating MYL5 and MYO1B are warranted. The gene discussed is IFNG; the disease is hepatocellular carcinoma.